Doxorubicin and multidrug resistance

Area of Science:

• Pharmacology
• Oncology
• Biochemistry

Background:

• Multidrug resistance (MDR) mediated by P-glycoprotein (P-gp) limits chemotherapy efficacy.
• Clinical trials focus on circumventing P-gp to enhance cytotoxicity of drugs like doxorubicin.
• The clinical significance of P-gp expression in solid tumors remains unclear.

Purpose of the Study:

• To evaluate strategies for overcoming P-glycoprotein-mediated multidrug resistance.
• To assess the feasibility of achieving effective concentrations of P-gp inhibitors.
• To explore alternative approaches to circumvent P-gp action in cancer therapy.

Main Methods:

• Review of clinical trials and laboratory studies on P-gp circumvention agents.
• Analysis of P-glycoprotein expression and its clinical significance.
• Investigation of pharmacologic agents, monoclonal antibodies, and liposome-encapsulated drugs.

Main Results:

• Initial studies show achievable concentrations of multidrug resistance modulators like cyclosporine.
• Pharmacologic P-gp inhibitors face an inherent barrier as they are substrates for P-gp.
• Alternative strategies like monoclonal antibodies and liposomal drug delivery show promise.

Conclusions:

• Overcoming P-glycoprotein-mediated multidrug resistance is crucial for improving cancer treatment.
• Achieving effective P-gp inhibitor levels without toxicity is a significant challenge.
• Alternative strategies offer potential solutions for circumventing P-gp in clinical settings.